Cogent Biosciences Inc (COGT) is a Healthcare · Biotechnology company listed on NASDAQ. Price $31.50 (-5.09%), Market cap $5.95B, 52-week low–high $4.77 ~ $42.11.
Cogent Biosciences, Inc., a clinical-stage biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor in Phase 3 trial designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company also develops CGT4859, a reversible and selective fibroblast growth factor receptor 2 inhibitor in Phase 1 trial for patients with documented FGFR mutations, including advanced c
Financial statements, price targets, institutional (13F) holdings and related news for Cogent Biosciences Inc are updated in real time on BlackAll Trade.
Cogent Biosciences Inc trades at $31.50 (-5.09%). Real-time quotes and charts are available on BlackAll Trade.
Cogent Biosciences Inc has a market cap of about $5.95B.
Cogent Biosciences, Inc., a clinical-stage biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486